{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:54:40Z","timestamp":1791831280957,"version":"4.3.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To assess the causes of death (COD) and long-term survival after nasopharyngeal carcinoma (NPC) diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using linked data from the Surveillance, Epidemiology, and End Results program, patients with NPC diagnosed from 1990 to 2010 and followed up &amp;gt;5 years were identified. Chi-squared test, the Kaplan\u2013Meier method, and the Cox proportional hazard model were used for analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 3,036 long-term NPC survivors, 1,432 survived for &amp;gt;5\u201310 years and 1,604 survived for &amp;gt;10 years. The most common COD was primary NPC (36.9%), followed by other causes (28.7%), other cancers (15.3%), cardiac disease (12.9%), and non-malignant pulmonary disease (6.2%). With a median follow-up of 125 months, deaths from NPC decreased with increasing time from diagnosis, while death because of cardiac disease and other causes increased. In those aged &amp;lt;50 years, death due to NPC remained the main COD over time, while cardiopulmonary disease-related death was the leading COD in patients aged \u226550 years. In White patients, death due to NPC decreased, and death due to cardiac disease increased over time. Death from NPC remained significant in Black and Asian patients even 15 years after the diagnosis of NPC, while death due to cardiac disease significantly increased after 9 years of diagnosis in Black patients. Multivariate analyses showed that the independent factors associated with inferior NPC-specific survival were older age, Asians, American Indian\/Alaska Native, regional stage, distant stage, and diagnosis in the early years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The probability of death from primary NPC remains significant even 15 years after the NPC diagnosis. Our study advocates continued surveillance for NPC survivors beyond the traditional 5 years. Individualized follow-up strategies are required for patients with NPC of different ages and races.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.912843","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T07:36:39Z","timestamp":1657179399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Causes of Death in Long-Term Nasopharyngeal Carcinoma Survivors"],"prefix":"10.3389","volume":"10","author":[{"given":"Shi-Ping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yue","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Shuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Lu","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.phrp.2016.11.002","article-title":"Epidemiology and inequality in the incidence and mortality of nasopharynx cancer in Asia","volume":"7","author":"Mahdavifar","year":"2016","journal-title":"Osong Public Health Res Perspect."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1002\/hed.26378","article-title":"Global, regional, and national burden of nasopharyngeal carcinoma from 1990 to 2017-results from the global burden of disease study 2017","volume":"42","author":"Hu","year":"2020","journal-title":"Head Neck."},{"key":"B3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/cncr.29795","article-title":"Proposal for the 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy","volume":"122","author":"Pan","year":"2016","journal-title":"Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1259\/bjr\/22373346","article-title":"Volumetric modulated arc therapy: a review of current literature and clinical use in practice","volume":"84","author":"Teoh","year":"2011","journal-title":"Br J Radiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.meddos.2013.09.004","article-title":"Dosimetric difference amongst 3 techniques: tomotherapy, sliding-window intensity-modulated radiotherapy (IMRT), and RapidArc radiotherapy in the treatment of late-stage nasopharyngeal carcinoma (NPC)","volume":"39","author":"Lee","year":"2014","journal-title":"Med Dosim."},{"key":"B6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1186\/s12885-019-6156-5","article-title":"The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis","volume":"19","author":"Zhi-Qiang","year":"2019","journal-title":"BMC Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"101216","DOI":"10.1016\/j.tranon.2021.101216","article-title":"Long-term outcomes of induction chemotherapy followed by intensity-modulated radiotherapy and adjuvant chemotherapy in nasopharyngeal carcinoma patients with N3 disease","volume":"14","author":"Niu","year":"2021","journal-title":"Transl Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.hoc.2021.05.007","article-title":"Nasopharyngeal carcinoma and its association with epstein-barr virus","volume":"35","author":"Vasudevan","year":"2021","journal-title":"Hematol Oncol Clin North Am."},{"key":"B13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial","volume":"119","author":"Yang","year":"2019","journal-title":"Eur J Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e045417","DOI":"10.1136\/bmjopen-2020-045417","article-title":"Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study","volume":"11","author":"Xu","year":"2021","journal-title":"BMJ Open."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/hed.25545","article-title":"Long-term outcome and pattern of failure for patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy","volume":"41","author":"Tian","year":"2019","journal-title":"Head Neck."},{"key":"B16","unstructured":"SEER*Stat Database: Incidence - SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000-2018) - Linked To County Attributes - Total U.S., 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission"},{"key":"B17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Bossi","year":"2021","journal-title":"Ann Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cac2.12218","article-title":"The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma","volume":"41","author":"Tang","year":"2021","journal-title":"Cancer Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1080\/03007995.2017.1322052","article-title":"Causes of death in long-term lung cancer survivors: a SEER database analysis","volume":"33","author":"Abdel-Rahman","year":"2017","journal-title":"Curr Med Res Opin."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1111\/ajco.13156","article-title":"Causes of death in long-term bladder cancer survivors: a population-based study","volume":"15","author":"Kong","year":"2019","journal-title":"Asia Pac J Clin Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.28588","article-title":"Causes of death in long-term survivors of head and neck cancer","volume":"120","author":"Baxi","year":"2014","journal-title":"Cancer."},{"key":"B22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.oraloncology.2016.12.006","article-title":"Competing causes of death in the head and neck cancer population","volume":"65","author":"Massa","year":"2017","journal-title":"Oral Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.oraloncology.2011.03.017","article-title":"Tobacco smoking, alcohol drinking, and the risk of different histological types of nasopharyngeal cancer in a low-risk population","volume":"47","author":"Polesel","year":"2011","journal-title":"Oral Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/ije\/dyab060","article-title":"Smoking and nasopharyngeal cancer: individual data meta-analysis of six prospective studies on 334,935 men","volume":"50","author":"Lin","year":"2021","journal-title":"Int J Epidemiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.oraloncology.2017.08.006","article-title":"Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: a population-based analysis","volume":"73","author":"Wu","year":"2017","journal-title":"Oral Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/coa.12371","article-title":"Survival outcome of patients with nasopharyngeal carcinoma: a nationwide analysis of 13 407 patients in Taiwan","volume":"40","author":"Huang","year":"2015","journal-title":"Clin Otolaryngol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/0194599816672625","article-title":"Racial and ethnic disparities in nasopharyngeal cancer survival in the United States","volume":"156","author":"Patel","year":"2017","journal-title":"Otolaryngol Head Neck Surg."},{"key":"B28","doi-asserted-by":"publisher","first-page":"11035","DOI":"10.21037\/apm-21-2835","article-title":"Trends in population mortality rates in the United States from 1969 to 2017","volume":"10","author":"Wu","year":"2021","journal-title":"Ann Palliat Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/coa.13225","article-title":"Survival differences in nasopharyngeal carcinoma among racial and ethnic minority groups in the United States: a retrospective cohort study","volume":"44","author":"Challapalli","year":"2019","journal-title":"Clin Otolaryngol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/aje\/kwk008","article-title":"Survival differences by race in nasopharyngeal carcinoma","volume":"165","author":"Sun LM Li","year":"2007","journal-title":"Am J Epidemiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"102288","DOI":"10.1016\/j.amjoto.2019.102288","article-title":"The racial disparity of nasopharyngeal carcinoma based on the database analysis","volume":"40","author":"Zhou","year":"2019","journal-title":"Am J Otolaryngol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.canep.2013.08.008","article-title":"Racial differences in nasopharyngeal carcinoma in the United States","volume":"37","author":"Wang","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.21037\/atm.2019.11.75","article-title":"The effect of histological subtypes on survival outcome in nasopharyngeal carcinoma after extensive follow up","volume":"7","author":"Wu","year":"2019","journal-title":"Ann Transl Med."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.912843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T07:36:44Z","timestamp":1657179404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.912843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":33,"alternative-id":["10.3389\/fpubh.2022.912843"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.912843","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"article-number":"912843"}}